SPCEO1 wrote: Exactly, as I said in a recent post, clinical success is a form of currency.
When you look at what Dr. Beliveau said in that TV program and in that article, he is basically telling us that something good has gone on in the pahse 1a trial. As you have also pointed out, you don't hire a siRNA specialist unless you at least have proof of concept.
So, while we do not know the exact dimensions of the clinical success TH has likely seen in the phase 1a, based on the signals we are getting, it is significant. If so, again as Dr. Beliveau indicated in that article, finding financing will not be a problem under those circumstances.
So, TH will soon be rolling into their phase 1b trial and may also finally get to move forward with their NASH trial as well. Will the money for this come from a NASH partner, a cancer partner's upfront payments, a share offering? I don't see a NASH partner yet. I think they have to prove it out in the small intial portion of the phase III trial to attract a real partner to finish off the NASH trial. While there may well be some money coming to TH from BGNE or another Chinese drug company, I am only going to put 50/50 odds on that right now. More likely, TH follows up good clincial news with some sort of share offering and uses that money to get the NASH phase III going.
So, soon, they could well be one of the few companies in the world with a phase III NASH trial in process and a very. very interesting phase 1b cancer trial where they will be able to select their patients for the level of sortilin overexpression. If they can get some decent analyst coverrage, then investors may start flocking to the stock in anticipation of early indications of success in the phase 1b trial in the not too distant future. So, it could get pretty exciting again but first we need that data to confirm our suspicions and then we need devent analyst and press coverage to get the word out to new potential TH investors.
jfm1330 wrote: All that is great, but it will all come down to the quality of the results. Something will happen if there is something interesting from Thera. Again, the best asset of a seller or a promoter is something good to sell or promote. The better the results will be, the more interest there will be.
SPCEO1 wrote: JP Morgan recently had their big healthcare conference and TH utilized that to have meetings with analysts, bankers and potential partners. JPM recently picked up coverage of BGNE with a 65 page report. Paul reported to shareholders he was meeting with that TH had a growing relationship with JPM and a JPM banker did something (I can't remember exactly what) on TH's LinkedIn site. TH wished people a Happy Chinese New Year for the first time ever on their LinkedIn site and Paul is following BGNE on LinkedIn. JPM was one of the underwriters of BGNE's recent offering on 12/15/21.
Could there be something more signinficant on the horizon than just a partership between BGNE and TH? Probably not but there are signs that a lot of talking is going on among these three entities and once you start talking you never know where it might lead. You know JPM would be keen to get something going where they earn a nice fee. TH could sell a stake in TH to BGNE to fund NASH and/or finance the potential redemption of the convert?
There is likely nothing there but where there is smoke there has to be a fire.